Bilimsel çalışmalar

Prof. Dr. Abdullah Sakin

247 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study

    Medicina, 2026

    DOI 10.3390/medicina62010214 PMID 41597500 Açık erişimli tam metinKaynak: OpenAlex

  2. Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group Study

    Clinical Medicine Insights Oncology, 2026

    DOI 10.1177/11795549261445290 PMID 42131419 Açık erişimli tam metinKaynak: OpenAlex

  3. First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis

    Medicina, 2026

    DOI 10.3390/medicina62050984 PMID 42195237 Açık erişimli tam metinKaynak: OpenAlex

  4. Real-world practices in RAS wild-type metastatic colorectal cancer patients treated with targeted agents in the first-line a nationwide onco-colon Turkey registry

    Anadolu Kliniği Tıp Bilimleri Dergisi, 2026

    DOI 10.21673/anadoluklin.1675424 Açık erişimli tam metinKaynak: OpenAlex

  5. Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-15725-9 PMID 41691201 Açık erişimli tam metinKaynak: OpenAlex

  6. Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective study

    Discover Oncology, 2026

    DOI 10.1007/s12672-026-04842-3 PMID 41870760 Açık erişimli tam metinKaynak: OpenAlex

  7. Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors

    Journal of Immunotherapy, 2026

    DOI 10.1097/cji.0000000000000604 PMID 41972337 Kaynak: OpenAlex

  8. Perioperative FLOT versus Definitive 50.4 Gy Chemoradiotherapy in Siewert II Esophagogastric Junction Adenocarcinoma: A Multicenter Retrospective Cohort Study

    Cancer Management and Research, 2026

    DOI 10.2147/cmar.s583473 PMID 42038552 Açık erişimli tam metinKaynak: OpenAlex

  9. Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study

    Cancers, 2026

    DOI 10.3390/cancers18121979 PMID 42352512 Açık erişimli tam metinKaynak: OpenAlex

  10. The role of serum adipokines in predicting response to neoadjuvant therapy in patients with locally advanced rectal cancer

    Revista da Associação Médica Brasileira, 2026

    DOI 10.1590/1806-9282.20251705 PMID 42585470 Açık erişimli tam metinKaynak: OpenAlex

  11. Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16868-5 Açık erişimli tam metinKaynak: OpenAlex

  12. Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma

    Immunotherapy, 2026

    DOI 10.1080/1750743x.2026.2722548 PMID 42683510 Açık erişimli tam metinKaynak: OpenAlex

  13. Resection and pathological response after neoadjuvant nivolumab plus chemotherapy for lung cancer in a Turkish Oncology Group (TOG) real-world study

    Research Square, 2026

    DOI 10.21203/rs.3.rs-11204389/v1 Açık erişimli tam metinKaynak: OpenAlex

  14. Comparison of First-Line Pembrolizumab Monotherapy Versus Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Multicenter Real-World Study from Turkey

    Medicina, 2026

    DOI 10.3390/medicina62112136 Açık erişimli tam metinKaynak: OpenAlex

  15. Prognostic and predictive value of systemic inflammatory markers in patients with metastatic gastric and GEJ adenocarcinoma with PD-L1 CPS score ≥ 5: Turkish Oncology Group (TOG) study

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-09707-3 PMID 40653542 5 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  16. The Association of Khorana Risk Score with Venous Thromboembolism and Overall Survival in Patients with Metastatic Gastric Cancer

    Medicina, 2025

    DOI 10.3390/medicina61061075 PMID 40572762 6 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  17. Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group

    International Journal of Cancer, 2025

    DOI 10.1002/ijc.70213 PMID 41147655 3 atıf (Europe PMC) Kaynak: OpenAlex

  18. Real-world comparison of doxorubicin–ifosfamide versus gemcitabine–docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study

    Discover Oncology, 2025

    DOI 10.1007/s12672-025-03886-1 PMID 41249604 Açık erişimli tam metinKaynak: OpenAlex

  19. Long-Term Oncological Outcomes for Locally Advanced Rectal Cancer Patients with Pathological Complete Response After Neoadjuvant Chemoradiotherapy: A Turkish Oncology Group Study

    Cancer Investigation, 2025

    DOI 10.1080/07357907.2025.2595536 PMID 41347635 1 atıf (Europe PMC) Kaynak: OpenAlex

  20. Efficacy of anti-VEGF & anti-EGFRs in microsatellite instable (MSI-H) metastatic colorectal cancer, Turkish Oncology Group (TOG) study.

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e15507 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  21. Survival Impact of Adjuvant Chemoradiotherapy in Resected Pancreatic Cancer

    Namık Kemal Tıp Dergisi, 2025

    DOI 10.4274/nkmj.galenos.2025.81994 Açık erişimli tam metinKaynak: OpenAlex

  22. Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program

    Future Oncology, 2025

    DOI 10.1080/14796694.2025.2570637 PMID 41103123 Açık erişimli tam metinKaynak: OpenAlex

  23. Impact of Blood Type on Treatment Response and Survival in HER2-Negative Metastatic Gastric Cancer

    Cerrahpasa Medical Journal, 2025

    DOI 10.5152/cjm.2025.25042 Açık erişimli tam metinKaynak: OpenAlex

  24. Efficacy and safety of doxorubicin–ifosfamide versus gemcitabine–docetaxel as first‐line therapy in advanced nonuterine leiomyosarcoma: A multicenter real‐world study

    International Journal of Cancer, 2025

    DOI 10.1002/ijc.70212 PMID 41147691 Kaynak: OpenAlex

  25. Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study

    Current Oncology, 2025

    DOI 10.3390/curroncol32110639 PMID 41294701 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  26. Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-15287-2 PMID 41275151 Açık erişimli tam metinKaynak: OpenAlex

  27. KRAS Mutasyonu Saptanmayan Metastatik Kolorektal Kanserli Hastalarda Anti-EGFR Kullanımı-Ulusal Onco-Colon Çalışması Gerçek Yaşam Verleri

    DergiPark (Istanbul University), 2025

    Kaynak: OpenAlex

  28. Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2366683 PMID 38904164 1 atıf (Europe PMC) Kaynak: OpenAlex

  29. Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2358458 PMID 38803194 Kaynak: OpenAlex

  30. Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study

    Cancers, 2024

    DOI 10.3390/cancers16193389 PMID 39410009 5 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  31. Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer

    BMC Cancer, 2024

    DOI 10.1186/s12885-023-11783-5 PMID 38166764 6 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  32. Perioperative 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in gastric cancer: Pathological regression grade and its relationship to clinical outcome

    Indian Journal of Cancer, 2024

    DOI 10.4103/ijc.ijc_1283_20 PMID 39960699 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  33. Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study

    Cancers, 2024

    DOI 10.3390/cancers16122251 PMID 38927957 4 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  34. Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study

    Breast Cancer Research and Treatment, 2024

    DOI 10.1007/s10549-024-07456-x PMID 39123071 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  35. Prognostic Significance of the Advanced Lung Cancer Inflammation Index in Metastatic Small Cell Lung Cancer: A Retrospective Analysis of 96 Patients

    Medical Science Monitor, 2024

    DOI 10.12659/msm.945752 PMID 39256975 5 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  36. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)

    Clinical Genitourinary Cancer, 2024

    DOI 10.1016/j.clgc.2024.102077 PMID 38626660 2 atıf (Europe PMC) Kaynak: OpenAlex

  37. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

    Medicine, 2024

    DOI 10.1097/md.0000000000037972 PMID 38787994 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  38. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

    Journal of Oncology Pharmacy Practice, 2024

    DOI 10.1177/10781552241241004 PMID 38613329 Açık erişimli tam metinKaynak: OpenAlex

  39. 1523P Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer

    Annals of Oncology, 2024

    DOI 10.1016/j.annonc.2024.08.1586 Kaynak: OpenAlex

  40. Association Between Body Mass Index and Survival in Patients with De Novo Metastatic Non-Small Cell Lung Cancer

    Medical Science Monitor, 2024

    DOI 10.12659/msm.946751 PMID 39690723 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  41. Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group

    The Oncologist, 2023

    DOI 10.1093/oncolo/oyad257 PMID 37676712 8 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  42. Clinical and inflammation marker features of cancer patients with COVID-19: data of Istanbul, Turkey multicenter cancer patients (2020–2022)

    Current Medical Research and Opinion, 2023

    DOI 10.1080/03007995.2023.2223917 PMID 37300513 5 atıf (Europe PMC) Kaynak: OpenAlex

  43. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

    BMC Cancer, 2023

    DOI 10.1186/s12885-023-10609-8 PMID 36765293 18 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  44. Major and minor salivary gland cancers: A multicenter retrospective study

    Head & Neck, 2023

    DOI 10.1002/hed.27376 PMID 37084179 8 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  45. PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study

    Journal of Geriatric Oncology, 2023

    DOI 10.1016/j.jgo.2023.101604 PMID 37683369 10 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  46. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study

    Journal of Cancer Research and Clinical Oncology, 2023

    DOI 10.1007/s00432-023-04766-3 PMID 37067546 7 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  47. Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study

    Neoplasma, 2023

    DOI 10.4149/neo_2022_221004n984 PMID 36620878 Açık erişimli tam metinKaynak: OpenAlex

  48. Comparison of the Efficacy of FOLFIRI and Paclitaxel Chemotherapy Regimens in the Second Line Treatment of Metastatic Gastric Cancer

    Van Sağlık Bilimleri Dergisi, 2023

    DOI 10.52976/vansaglik.1308883 Kaynak: OpenAlex

  49. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-03984-5 PMID 35381885 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  50. First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal carcinoma

    Bosnian Journal of Basic Medical Sciences, 2022

    DOI 10.17305/bjbms.2021.7069 PMID 35460397 4 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex